Healthcare

Cash, cash equivalents and marketable securities totaled $228.9 million at September 30, 2026, compared with the prior comparison date cited in the company's report. The company stated that this balance provides a runway into the first half of the following year, according to the …

Revenue grew 5% year over year to $123.1 million. Exome and genome test revenue grew 12% to $110.4 million. The company reported exome and genome accession growth of 28% year over year, with test result volume growing 25%.

The trials address chronic cough in patients with idiopathic pulmonary fibrosis, non-IPF interstitial lung disease and refractory chronic cough.

The first patient dosing in the SZN-8141 DUET study marks the start of clinical testing in the program, which the company described as its next stage.

Consolidated revenue fell because the company divested its Idaho Falls facilities, which it owned through September 13, 2026.

Contract revenue for the three months ended September 30, 2026, was $1.7 million, compared with no contract revenue for the same period of 2025. The increase was primarily attributable to a collaboration and license agreement with Chugai, according to the company's report of its …

Sample Management Solutions revenue was $12.5 million in the third quarter, an increase of 21% from the prior-year period.